PURPOSE: To describe genitourinary (GU) toxicity in men with a history of transurethral resection of the prostate (TURP) treated with external beam radiation therapy (EBRT) for prostate cancer. METHODS AND MATERIALS: Seventy-one men with a history of TURP were treated with EBRT for prostate cancer. The median time from TURP to EBRT was 15 months. The median EBRT dose was 70 Gy, and 21 men (30%) received androgen deprivation therapy (ADT). Acute GU toxicity and late GU toxicity were scored by Radiation Therapy Oncology Group criteria and compared with a cohort of 538 men without prior TURP. The median follow-up for men with TURP and men without TURP was 40 months and 50 months, respectively (p = 0.7605). RESULTS: The rate of acute Grade 2 GU toxicity or higher was 41%, and was increased with a history of more than 1 TURP (73% vs. 31%, p = 0.0036). The 4-year rate of freedom from late Grade 3 GU toxicity or higher was 84%, and was decreased with ADT (45% vs. 95% without ADT, p = 0.0024). By last follow-up, maximal GU toxicity tended to resolve (p < 0.0001) and there was no worsening of urinary symptom scores (p = 0.6911). Compared to men without a prior TURP, TURP patients had a lower rate of freedom from late Grade 3 toxicity or higher (84% vs. 96%, p = 0.0483). Multivariate analysis suggested a higher rate of late Grade 3 toxicity or higher with TURP (risk ratio, 2.87; p = 0.0612) and EBRT dose of 74 Gy or greater (risk ratio, 2.26; p = 0.0521). CONCLUSIONS: Men treated for prostate cancer with EBRT after TURP have a higher risk of severe GU toxicity; however, the overall incidence is low, and toxicity tends not to persist. Copyright 2010 Elsevier Inc. All rights reserved.
PURPOSE: To describe genitourinary (GU) toxicity in men with a history of transurethral resection of the prostate (TURP) treated with external beam radiation therapy (EBRT) for prostate cancer. METHODS AND MATERIALS: Seventy-one men with a history of TURP were treated with EBRT for prostate cancer. The median time from TURP to EBRT was 15 months. The median EBRT dose was 70 Gy, and 21 men (30%) received androgen deprivation therapy (ADT). Acute GU toxicity and late GU toxicity were scored by Radiation Therapy Oncology Group criteria and compared with a cohort of 538 men without prior TURP. The median follow-up for men with TURP and men without TURP was 40 months and 50 months, respectively (p = 0.7605). RESULTS: The rate of acute Grade 2 GU toxicity or higher was 41%, and was increased with a history of more than 1 TURP (73% vs. 31%, p = 0.0036). The 4-year rate of freedom from late Grade 3 GU toxicity or higher was 84%, and was decreased with ADT (45% vs. 95% without ADT, p = 0.0024). By last follow-up, maximal GU toxicity tended to resolve (p < 0.0001) and there was no worsening of urinary symptom scores (p = 0.6911). Compared to men without a prior TURP, TURP patients had a lower rate of freedom from late Grade 3 toxicity or higher (84% vs. 96%, p = 0.0483). Multivariate analysis suggested a higher rate of late Grade 3 toxicity or higher with TURP (risk ratio, 2.87; p = 0.0612) and EBRT dose of 74 Gy or greater (risk ratio, 2.26; p = 0.0521). CONCLUSIONS:Men treated for prostate cancer with EBRT after TURP have a higher risk of severe GU toxicity; however, the overall incidence is low, and toxicity tends not to persist. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Sarah L Kerns; Ashley Amidon Morlang; Sharon M Lee; Derick R Peterson; Brian Marples; Hong Zhang; Kevin Bylund; Doug Rosenzweig; William Hall; Kim De Ruyck; Barry S Rosenstein; Richard G Stock; Antonio Gómez-Caamaño; Ana Vega; Paloma Sosa-Fajardo; Begoña Taboada-Valladares; Miguel E Aguado-Barrera; Chris Parker; Liv Veldeman; Valérie Fonteyne; Renée Bultijnck; Christopher J Talbot; R Paul Symonds; Kerstie Johnson; Tim Rattay; Adam Webb; Maarten Lambrecht; Dirk de Ruysscher; Ben Vanneste; Ananya Choudhury; Rebecca M Elliott; Elena Sperk; Carsten Herskind; Marlon R Veldwijk; Tiziana Rancati; Barbara Avuzzi; Riccardo Valdagni; David Azria; Marie-Pierre Farcy Jacquet; Jenny Chang-Claude; Petra Seibold; Catharine West; Michelle Janelsins; Yuhchyau Chen; Edward Messing; Gary Morrow Journal: Radiother Oncol Date: 2022-01-22 Impact factor: 6.280
Authors: Marie K Gurka; Leonard N Chen; Aditi Bhagat; Rudy Moures; Joy S Kim; Thomas Yung; Siyuan Lei; Brian T Collins; Pranay Krishnan; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins Journal: Radiat Oncol Date: 2015-02-19 Impact factor: 3.481
Authors: Jennifer A Woo; Leonard N Chen; Aditi Bhagat; Eric K Oermann; Joy S Kim; Rudy Moures; Thomas Yung; Siyuan Lei; Brian T Collins; Deepak Kumar; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins Journal: Front Oncol Date: 2014-05-26 Impact factor: 6.244
Authors: Abigail Pepin; Nima Aghdam; Sarthak Shah; Shaan Kataria; Harry Tsou; Subhradeep Datta; Malika Danner; Marilyn Ayoob; Thomas Yung; Siyuan Lei; Marie Gurka; Brian T Collins; Pranay Krishnan; Simeng Suy; Ryan Hankins; John H Lynch; Sean P Collins Journal: Front Oncol Date: 2020-05-05 Impact factor: 6.244
Authors: Derek T Lee; Nancy P Mendenhall; Tamara L Smith; Christopher G Morris; Romaine C Nichols; Curtis Bryant; Randal H Henderson; William M Mendenhall; Joseph Costa; Christopher R Williams; Zuofeng Li; Bradford S Hoppe Journal: Int J Part Ther Date: 2016
Authors: Ofer N Gofrit; Ran Katz; Amos Shapiro; Vladimir Yutkin; Galina Pizov; Kevin C Zorn; Mordechai Duvdevani; Ezekiel H Landau; Dov Pode Journal: ISRN Surg Date: 2013-03-24
Authors: Randal H Henderson; Bradford S Hoppe; Robert B Marcus; William M Mendenhall; R Charles Nichols; Zuofeng Li; Zhong Su; Christopher G Morris; Christopher R Williams; Joseph Costa; Nancy P Mendenhall Journal: Acta Oncol Date: 2013-04 Impact factor: 4.089
Authors: W Tristram Arscott; Leonard N Chen; Nathan Wilson; Aditi Bhagat; Joy S Kim; Rudy A Moures; Thomas M Yung; Siyuan Lei; Brian T Collins; Keith Kowalczyk; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins Journal: Radiat Oncol Date: 2014-07-24 Impact factor: 3.481
Authors: Mélanie Guilhen; Christophe Hennequin; Idir Ouzaid; Ingrid Fumagalli; Valentine Martin; Sophie Guillerm; Pierre Mongiat-Artus; Vincent Ravery; François Desgrandchamps; Laurent Quéro Journal: Radiat Oncol Date: 2018-10-24 Impact factor: 3.481